Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AXGN
stocks logo

AXGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
57.94M
+17.27%
-0.018
-283.3%
57.22M
+17.84%
-0.026
-67.5%
64.45M
+13.74%
0.042
+320%
Estimates Revision
The market is revising Upward the revenue expectations for Axogen, Inc. (AXGN) for FY2025, with the revenue forecasts being adjusted by 1.64% over the past three months. During the same period, the stock price has changed by 105.60%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.64%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-20.37%
In Past 3 Month
Stock Price
Go Up
up Image
+105.60%
In Past 3 Month
Wall Street analysts forecast AXGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 29.20 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AXGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 29.20 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.855
sliders
Low
26.00
Averages
29.20
High
34.00
Current: 32.855
sliders
Low
26.00
Averages
29.20
High
34.00
H.C. Wainwright
Buy
maintain
$25 -> $26
2025-10-30
Reason
H.C. Wainwright
Price Target
$25 -> $26
2025-10-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on AxoGen to $26 from $25 and keeps a Buy rating on the shares. The company reported a Q3 beat and upped its 2025 outlook, the analyst tells investors in a research note. The firm believes AxoGen's execution of its market development strategy should drive revenue growth in the coming quarters.
Citizens JMP
Outperform
maintain
$26 -> $34
2025-10-30
Reason
Citizens JMP
Price Target
$26 -> $34
2025-10-30
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on AxoGen to $34 from $26 and keeps an Outperform rating on the shares. Sales of $60.1M reflected another all-time quarterly record in dollars and represented the second-best top-line growth performance in four years, the analyst tells investors in a research note. AxoGen has truly differentiated products for nerve protection and repair, and a biologics license application could help make Avance the standard-of-care solution in peripheral nerve repair over time, Citizens argues.
Canaccord
Buy
maintain
$24 -> $27
2025-10-30
Reason
Canaccord
Price Target
$24 -> $27
2025-10-30
maintain
Buy
Reason
Canaccord raised the firm's price target on AxoGen to $27 from $24 and keeps a Buy rating on the shares. The fim said posted yet another strong Q as the company saw traction across its portfolio, growing over 23%, significantly above consensus expectations, and raising guidance to over 19% growth for the FY25.
Jefferies
Buy
maintain
$25 -> $29
2025-10-29
Reason
Jefferies
Price Target
$25 -> $29
2025-10-29
maintain
Buy
Reason
Jefferies raised the firm's price target on AxoGen to $29 from $25 and keeps a Buy rating on the shares after Q3 sales beat consensus by about 6% and the company raised FY25 sales growth guidance to at least 19% year-over-year. The Q3 report "showed solid execution all around," the analyst tells investors.
H.C. Wainwright
Yi Chen
Buy
initiated
$25
2025-09-30
Reason
H.C. Wainwright
Yi Chen
Price Target
$25
2025-09-30
initiated
Buy
Reason
H.C. Wainwright analyst Yi Chen initiated coverage of AxoGen with a Buy rating and $25 price target. Axogen is a ommercial-stage medical device company focused on development of products for peripheral nerve regeneration and repair, the analyst tells investors in a research note. The firm says near-term FDA approval could expand adoption of Avance. It expects AxoGen to see solid sales growth in the coming years.
Raymond James
Jayson Bedford
Outperform
downgrade
$21 -> $20
2025-08-06
Reason
Raymond James
Jayson Bedford
Price Target
$21 -> $20
2025-08-06
downgrade
Outperform
Reason
Raymond James analyst Jayson Bedford lowered the firm's price target on AxoGen to $20 from $21 and keeps an Outperform rating on the shares. AxoGen's Q2 results demonstrated a step-up in momentum, with improvement seen in both revenue growth and gross margin, and while the low end of second half guidance implies a growth deceleration, this appears to be conservative given recent trends and contribution from newly added reps, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for AxoGen Inc (AXGN.O) is 616.42, compared to its 5-year average forward P/E of -17.31. For a more detailed relative valuation and DCF analysis to assess AxoGen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.31
Current PE
616.42
Overvalued PE
199.05
Undervalued PE
-233.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
21.66
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
126.88
Undervalued EV/EBITDA
-83.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.16
Current PS
0.00
Overvalued PS
4.56
Undervalued PS
1.77
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2920% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AXGN News & Events

Events Timeline

(ET)
2025-12-04
16:20:00
Major Averages Close Little Changed as Jobless Claims Fall to 191,000
select
2025-12-04
12:00:00
Major U.S. Indices Little Changed as Investors Anticipate Fed Rate Cut
select
2025-12-04
07:10:00
Axogen Receives FDA Approval for Avance Biologics License Application
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:29 AMBenzinga
PinnedAxogen Reaches New 52-Week Peak Following FDA Approval of Innovative Nerve Repair Therapy

  • FDA Approval: The FDA approved Axogen Inc.'s Avance, an acellular nerve scaffold for patients with peripheral nerve discontinuities, allowing for treatment without the need for a second surgical site.

  • Clinical Benefits: The approval was granted under the Accelerated Approval pathway, with continued approval dependent on further confirmatory studies demonstrating clinical benefits.

  • Financial Performance: Axogen reported a 23.5% year-over-year revenue increase in Q3, reaching $60.1 million, and raised its 2025 revenue guidance to at least 19% growth.

  • Stock Performance: Following the news, Axogen's stock rose 18.78% to $31.01, marking a new 52-week high.

[object Object]
Preview
9.0
12-04Newsfilter
PinnedAxogen Receives FDA Approval for AVANCE Biologics, Advancing Nerve Repair Technology
  • FDA Approval: Axogen's AVANCE® biologic has received FDA approval for treating peripheral nerve discontinuities in patients aged one month and older, marking a significant milestone that is expected to enhance the company's competitive position in the nerve repair market.
  • Accelerated Approval Pathway: The indications for AVANCE include sensory nerve discontinuities (≤25mm) and mixed/motor nerve discontinuities, which were approved based on static two-point discrimination outcomes, indicating potential clinical benefits and aligning with FDA's expedited review process.
  • Commercialization Plans: The licensed AVANCE product is expected to be commercially available in early Q2 2026, while it remains accessible under the current tissue framework, demonstrating the company's proactive approach to market introduction of new products.
  • Strategic Transformation: This approval transitions AVANCE from a human tissue product to a biologic, strengthening Axogen's regulatory footing and ensuring recognition of its therapeutic options in nerve repair, further advancing the company's mission to standardize nerve restoration care.
[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedFDA Grants Approval for Axogen's AVANCE Nerve Allograft to Repair Peripheral Nerves

  • FDA Approval: Axogen, Inc. received FDA approval for its Biologics License Application (BLA) for AVANCE, an acellular nerve allograft designed to treat peripheral nerve discontinuities in patients aged one month and older.

  • Stock Performance: Following the announcement, Axogen's stock rose from $28.33 to $30.07, reflecting a 6.14% increase in after-hours trading.

  • Therapeutic Indications: The approval covers sensory nerve discontinuities greater than 25mm, as well as mixed and motor nerve discontinuities, based on evidence of improved sensory function.

  • Future Availability: The commercial launch of AVANCE is anticipated in early Q2 2026, while it remains accessible under the current tissue framework until then.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AxoGen Inc (AXGN) stock price today?

The current price of AXGN is 32.855 USD — it has increased 15.97 % in the last trading day.

arrow icon

What is AxoGen Inc (AXGN)'s business?

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

arrow icon

What is the price predicton of AXGN Stock?

Wall Street analysts forecast AXGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 29.20 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AxoGen Inc (AXGN)'s revenue for the last quarter?

AxoGen Inc revenue for the last quarter amounts to 60.08M USD, increased 23.51 % YoY.

arrow icon

What is AxoGen Inc (AXGN)'s earnings per share (EPS) for the last quarter?

AxoGen Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for AxoGen Inc (AXGN)'s fundamentals?

The market is revising Upward the revenue expectations for Axogen, Inc. (AXGN) for FY2025, with the revenue forecasts being adjusted by 1.64% over the past three months. During the same period, the stock price has changed by 105.60%.
arrow icon

How many employees does AxoGen Inc (AXGN). have?

AxoGen Inc (AXGN) has 451 emplpoyees as of December 05 2025.

arrow icon

What is AxoGen Inc (AXGN) market cap?

Today AXGN has the market capitalization of 1.52B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free